COVID-19 geçiren, CoronaVac ve BNT162b2 aşı olan bireylerde hümoral immün yanıtın değerlendirilmesi
Yükleniyor...
Dosyalar
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Harran Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Günümüzde COVID-19 aşılaması ya da geçirilmiş enfeksiyon sonrasında humoral immün yanıtı değerlendirmek amacıyla pek çok immünolojik test yöntemi kullanılmaktadır. Çalışmamızda CoronaVac, veya BNT162b2 ile aşılanan ve COVID-19 geçiren kişilerde SARS-CoV-2 humoral immün yanıtı üç farklı immünolojik test yöntemiyle değerlendirmeyi amaçladık. Materyal ve metod: COVID-19 tanısı alan 30, CoronaVac aşısı olan 35 ve BNT162b2 aşısı olan 35 kişinin 28 gün sonra alınan serum örnekleri çalışmaya dahil edilmiştir. SARS-CoV 2’nin spike proteini S1 alt biriminin reseptör bağlayıcı bölgesine (RBD) karşı nötralize edici antikorlar üç farklı prensibe yönelik (CMIA, ELISA, LFA) antikor testleri ile (ARCHITECT IgG II Quant test, Abbott, USA/SARS-CoV-2 NeutraLISA, Euroimmun, Lübeck, Almanya/ NeutraXpress™, JOYSBIO Biotechnology Co. Ltd., Tianjin China) çalışıldı. Verilerin istatistiksel değerlendirmesinde IBM SPSS 21.0 paket programı kullanıldı. Bulgular: Tüm olguların SARS-CoV-2 kantitatif antikor titreleri 2635,150 (391,1-8053,425) AU/mL olarak saptandı. Gruplar arasındaki istatistiksel değerlendirmede, COVID-19 geçiren ve BNT162b2 aşısı olan kişilerin SARS-CoV-2 kantitatif antikor titreleri, CoronaVac ile aşılı gruba kıyasla anlamlı olarak yüksek saptandı (p<0.001). SARS-CoV-2 nötralizan antikor inhibisyon yüzdesi tüm olgularda %88,4 (32,9-98,8) iken, COVID-19 geçiren ve BNT162b2 aşısı olanlarda anlamlı olarak yüksek saptandı (p<0.001). Lateral-flow yöntemine göre bağlanan total antikor varlığı 75 (%75) kişide pozitif olarak saptanırken, nötralizan antikor 60 (%60) kişide pozitif olarak saptandı. Sonuç: Çalışmamızın sonuçlarına göre, enfeksiyon ve aşılama sonrası SARS-CoV-2’ye spesifik humoral immün yanıtın geliştiği görülmektedir. Ayrıca, immünolojik yöntemlerle humoral immün yanıtın değerlendirilmesinde, duyarlılığı ve özgüllüğü yüksek olan testlerin tercih edilmesi gerektiğini düşünmekteyiz.
Background: Currently, many immunological test methods are used to evaluate the humoral immune response after COVID-19 vaccination or infection. In our study, we aimed to evaluate the SARS-CoV-2 humoral immune response in people who had implemented CoronaVac, BNT162b2 and diagnosed with COVID-19 with different immunological test methods. Materials and Methods: Serum samples from 30 people diagnosed with COVID-19, 35 people with CoronaVac vaccine and 35 people with BNT162b2 vaccine taken 28 days later were included in the study. Neutralizing antibodies against the receptor-binding region (RBD) of the spike protein S1 subunit of SARS-CoV 2, with antibody tests against three different principles (CMIA, ELISA, LFA) (ARCHITECT IgG II Quant test, Abbott, USA/SARS-CoV- 2 NeutraLISA, Euroimmun, Lübeck, Germany/ NeutraXpress™, JOYSBIO Biotechnology Co. Ltd., Tianjin China) were studied. IBM SPSS statistic 21 package program was used for the statistical evaluation of the data. Results: SARS-CoV-II quantitative antibody titers of all cases were found to be 2635,150 (391.1-8053,425) AU/mL.In the statistical evaluation between the groups, the SARS-CoV-2 quantitative antibody titers of the people who had COVID-19 and were vaccinated with BNT162b2 were found to be significantly higher than the CoronaVac group (p<0.001). While the percentage of SARS-CoV-2 neutralizing antibody inhibition was 88,4% (32,9-98,8) in all cases, it was found to be significantly higher in those who had COVID-19 and had BNT162b2 vaccine (p<0.001). While the presence of total antibodies bound by the lateral-flow method was positive in 75 (75%) individuals, Neutralizing antibody was positive in 60 (60%) individuals. Conclusions: According to the results of our study, a specific humoral immune response to SARS-CoV-2 develops after both infection and vaccination. In addition, we think that the tests with high sensitivity and specificity should be preferred in the evaluation of humoral immune response by immunological methods.
Background: Currently, many immunological test methods are used to evaluate the humoral immune response after COVID-19 vaccination or infection. In our study, we aimed to evaluate the SARS-CoV-2 humoral immune response in people who had implemented CoronaVac, BNT162b2 and diagnosed with COVID-19 with different immunological test methods. Materials and Methods: Serum samples from 30 people diagnosed with COVID-19, 35 people with CoronaVac vaccine and 35 people with BNT162b2 vaccine taken 28 days later were included in the study. Neutralizing antibodies against the receptor-binding region (RBD) of the spike protein S1 subunit of SARS-CoV 2, with antibody tests against three different principles (CMIA, ELISA, LFA) (ARCHITECT IgG II Quant test, Abbott, USA/SARS-CoV- 2 NeutraLISA, Euroimmun, Lübeck, Germany/ NeutraXpress™, JOYSBIO Biotechnology Co. Ltd., Tianjin China) were studied. IBM SPSS statistic 21 package program was used for the statistical evaluation of the data. Results: SARS-CoV-II quantitative antibody titers of all cases were found to be 2635,150 (391.1-8053,425) AU/mL.In the statistical evaluation between the groups, the SARS-CoV-2 quantitative antibody titers of the people who had COVID-19 and were vaccinated with BNT162b2 were found to be significantly higher than the CoronaVac group (p<0.001). While the percentage of SARS-CoV-2 neutralizing antibody inhibition was 88,4% (32,9-98,8) in all cases, it was found to be significantly higher in those who had COVID-19 and had BNT162b2 vaccine (p<0.001). While the presence of total antibodies bound by the lateral-flow method was positive in 75 (75%) individuals, Neutralizing antibody was positive in 60 (60%) individuals. Conclusions: According to the results of our study, a specific humoral immune response to SARS-CoV-2 develops after both infection and vaccination. In addition, we think that the tests with high sensitivity and specificity should be preferred in the evaluation of humoral immune response by immunological methods.
Açıklama
Anahtar Kelimeler
BNT162b2, CoronaVac, CLIA, ELISA, LFA, COVID-19
Kaynak
Harran Üniversitesi Tıp Fakültesi Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
19
Sayı
3
Künye
Gareayaghi, N., Dinç, H. Ö., Özbey, D., Akçin, R., Daşdemir, F., Akkuş, S., Eryiğit, Ö. Y., & Kocazeybek, B. (2022). COVID-19 geçiren, CoronaVac ve BNT162b2 aşı olan bireylerde hümoral immün yanıtın değerlendirilmesi. Harran Üniversitesi Tıp Fakültesi Dergisi, 19(3), pp. 576-580. https://doi.org/10.35440/hutfd.1138445
